Lipanthyl

Fenofibrate, the active ingredient in Lipanthyl, is a fibrate presented as an oral tablet formulation for oral administration. It is indicated for the management of elevated triglyceride and cholesterol concentrations in adult patients with dyslipidemia, contributing to the reduction of atherogenic lipid particles and associated cardiovascular risk.

GNH USA supplies Lipanthyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, with established quality‑assured manufacturing and regulatory compliance, and reliable logistics support for global distribution.

Lipanthyl (fenofibrate) is used to treat lipid disorders by reducing triglyceride synthesis and enhancing fatty‑acid oxidation.

- Hypertriglyceridemia: lowers very high triglyceride levels, helping to prevent pancreatitis. - Mixed dyslipidemia: reduces triglycerides and modestly increases HDL‑cholesterol while lowering LDL‑cholesterol. - Primary hypercholesterolemia: decreases total cholesterol and LDL‑cholesterol as part of combination therapy.

Fenofibrate may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Elevated liver enzymes: transient increase in ALT or AST. - Muscle pain: mild myalgia without weakness. - Headache: occasional tension‑type headache. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Gallstones: formation of biliary sludge or stones. - Severe allergic reactions: anaphylaxis or angioedema. - Blood dyscrasias: thrombocytopenia or leukopenia.

Before initiating Lipanthyl, clinicians should consider several precautionary measures to ensure safe use. - Liver function: assess baseline hepatic enzymes and monitor periodically. - Renal function: evaluate kidney function, especially in patients with impairment. - Muscle disorders: avoid in patients with active myopathy or uncontrolled hypothyroidism. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis. - Anticoagulants (warfarin): potentiation of anticoagulant effect, requiring INR monitoring. - Bile acid sequestrants: may reduce fenofibrate absorption.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil): increase fenofibrate plasma levels. - Immunosuppressants (e.g., cyclosporine): may elevate serum concentrations. - Oral contraceptives: possible alteration of lipid parameters.